Circulating cholesteryl ester transfer protein and coronary heart disease: Mendelian randomization meta-analysis

Circulation: Cardiovascular Genetics

Volumn 8, Issue 1, 2015, Pages 114-121

  Niu, Wenquan ^a   Qi, Yue ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

analysis meta analysis; cholesterol; coronary disease; HDL; Mendelian randomization

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CETP PROTEIN, HUMAN; CHOLESTEROL;

ALLELISM; ARTICLE; CARDIOVASCULAR RISK; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; ALLELE; BIOLOGICAL MODEL; BLOOD; CORONARY ARTERY DISEASE; GENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ALLELES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; HUMANS; MODELS, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84924606733     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000748     Document Type: Article

References (64)

1. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338:86-93. doi: 10.1056/NEJM199801083380203.
2. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580. doi: 10.1016/S0140-6736(12)60312-2.
3. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. doi: 10.1056/NEJMoa0706628.
4. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099. doi: 10.1056/NEJMoa1206797.
5. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis. 2001;159:187-192.
6. Kappelle PJ, Gansevoort RT, Hillege HJ, Wolffenbuttel BH, Dullaart RP; PREVEND Study Group. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. J Clin Lipidol. 2013;7:56-64. doi: 10.1016/j.jacl.2012.05.003.
7. Keavney B, Palmer A, Parish S, Clark S, Youngman L, Danesh J, et al International Studies of Infarct Survival (ISIS) Collaborators. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol. 2004;33:1002-1013. doi: 10.1093/ije/dyh275.
8. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest. 1995;96:1664-1671. doi: 10.1172/JCI118207.
9. Marschang P, Sandhofer A, Ritsch A, Fi͉er I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med . 2006;260:151-159. doi: 10.1111/j.1365-2796.2006.01674.x.
10. Tsai MY, Johnson C, Kao WH, Sharrett AR, Arends VL, Kronmal R, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200:359-367. doi: 10.1016/j.atherosclerosis.2007.12.038.
11. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-2788. doi: 10.1001/jama.299.23.2777.
12. Niu W, Liu Y, Qi Y, Wu Z, Zhu D, Jin W. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157:243-252. doi: 10.1016/j.ijcard.2011.12.098.
13. Lewis SJ. Mendelian randomization as applied to coronary heart disease, including recent advances incorporating new technology. Circ Cardiovasc Genet. 2010;3:109-117. doi: 10.1161/CIRCGENETICS.109.880955.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
15. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105-114. doi: 10.1016/j.cct.2006.04.004.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. doi: 10.1136/bmj.327.7414.557.
17. Minelli C, Thompson JR, Tobin MD, Abrams KR. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol. 2004;160:445-452. doi: 10.1093/aje/kwh228.
18. Wang J, Wang LJ, Zhong Y, Gu P, Shao JQ, Jiang SS, et al. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids Health Dis. 2013;12:176. doi: 10.1186/1476-511X-12-176.
19. Lu Y, Tayebi N, Li H, Saha N, Yang H, Heng CK. Association of CETP Taq1B and -629C > A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population. Lipids Health Dis. 2013;12:85. doi: 10.1186/1476-511X-12-85.
20. Rahimi Z, Nourozi-Rad R, Vaisi-Raygani A, Saidi MR, Rahimi Z, Ahmadi R, et al. Association between cholesteryl ester transfer protein TaqIB variants and risk of coronary artery disease and diabetes mellitus in the population of western Iran. Genet Test Mol Biomarkers. 2011;15:813-819. doi: 10.1089/gtmb.2011.0037.
21. Kolovou G, Vasiliadis I, Kolovou V, Karakosta A, Mavrogeni S, Papadopoulou E, et al. The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease. Lipids Health Dis. 2011;10:156. doi: 10.1186/1476-511X-10-156.
22. Tanrikulu-Kucuk S, Ademoglu E, Gurdol F, Bilge AK, Mutlu-Turkoglu U, Nisanci Y. Cholesteryl ester transfer protein Taq1B polymorphism in an angiographically assessed Turkish population: no effects on coronary artery disease risk. Genet Test Mol Biomarkers. 2010;14:637-642. doi: 10.1089/gtmb.2010.0069.
23. Kaestner S, Patsouras N, Spathas DH, Flordellis CS, Manolis AS. Lack of association between the cholesteryl ester transfer protein gene-TaqIB polymorphism and coronary restenosis following percutaneous transluminal coronary angioplasty and stenting: a pilot study. Angiology. 2010;61:338-343. doi: 10.1177/0003319709348297.
24. Corella D, Carrasco P, Amiano P, Arriola L, Chirlaque MD, Huerta JM, et al. Common cholesteryl ester transfer protein gene variation related to high-density lipoprotein cholesterol is not associated with decreased coronary heart disease risk after a 10-year follow-up in a Mediterranean cohort: modulation by alcohol consumption. Atherosclerosis. 2010;211:531-538. doi: 10.1016/j.atherosclerosis.2010.03.026.
25. Bhanushali AA, Das BR. Genetic variants at the APOE, lipoprotein lipase (LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk of CAD in Asian Indians. J Community Genet. 2010;1:55-62. doi: 10.1007/s12687-010-0005-1.
26. Poduri A, Khullar M, Bahl A, Sharma YP, Talwar KK. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol. 2009;28:451-460. doi: 10.1089/dna.2009.0887.
27. Padmaja N, Kumar RM, Balachander J, Adithan C. Cholesteryl ester transfer protein TaqIB, -629C>A and I405V polymorphisms and risk of coronary heart disease in an Indian population. Clin Chim Acta. 2009;402:139-145. doi: 10.1016/j.cca.2008.12.041.
28. Izar MC, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, et al GOLD Investigators. Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis. 2009;204:165-170. doi: 10.1016/j.atherosclerosis.2008.08.006.
29. van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, et al REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008;200:161-167. doi: 10.1016/j.atherosclerosis.2007.11.019.
30. Rejeb J, Omezzine A, Rebhi L, Naffeti I, Kchok K, Belkahla R, et al. Association of the cholesteryl ester transfer protein Taq1 B2B2 genotype with higher high-density lipoprotein cholesterol concentrations and lower risk of coronary artery disease in a Tunisian population. Arch Cardiovasc Dis. 2008;101:629-636. doi: 10.1016/j.acvd.2008.09.013.
31. Muendlein A, Saely CH, Marte T, Schmid F, Koch L, Rein P, et al. Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. Atherosclerosis. 2008;199:179-186. doi: 10.1016/j.atherosclerosis.2007.10.030.
32. Meiner V, Friedlander Y, Milo H, Sharon N, Ben-Avi L, Shpitzen S, et al. Cholesteryl ester transfer protein (CETP) genetic variation and early onset of non-fatal myocardial infarction. Ann Hum Genet. 2008;72(Pt 6):732-741. doi: 10.1111/j.1469-1809.2008.00464.x.
33. Jensen MK, Mukamal KJ, Overvad K, Rimm EB. Alcohol consumption, TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women. Eur Heart J. 2008;29:104-112. doi: 10.1093/eurheartj/ehm517.
34. Hsieh MC, Tien KJ, Chang SJ, Lo CS, Hsin SC, Hsiao JY, et al. Cholesteryl ester transfer protein B1B1 genotype as a predictor of coronary artery disease in Taiwanese with type 2 diabetes mellitus. Metabolism. 2007;56:745-750. doi: 10.1016/j.metabol.2006.12.023.
35. Dedoussis GV, Panagiotakos DB, Louizou E, Mantoglou I, Chrysohoou C, Lamnisou K, et al. Cholesteryl ester-transfer protein (CETP) polymorphism and the association of acute coronary syndromes by obesity status in Greek subjects: the CARDIO2000-GENE study. Hum Hered. 2007;63:155-161. doi: 10.1159/000099827.
36. Yilmaz H, Isbir T, Agachan B, Karaali ZE. Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. Cell Biochem Funct. 2005;23:23-28. doi: 10.1002/cbf.1124.
37. Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, et al Intermountain Heart Collaborative Study Group. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J. 2005;150:243-250. doi: 10.1016/j.ahj.2004.08.034.
38. Falchi A, Giovannoni L, Piras IS, Calo CM, Moral P, Vona G, et al. Prevalence of genetic risk factors for coronary artery disease in Corsica island (France). Exp Mol Pathol. 2005;79:210-213. doi: 10.1016/j.yexmp.2005.09.005.
39. Zheng KQ, Zhang SZ, He Y, Zhang L, Zhang KL, Huang DJ, et al. Association between cholesteryl ester transfer protein gene polymorphisms and variations in lipid levels in patients with coronary heart disease. Chin Med J (Engl). 2004;117:1288-1292.
40. Zee RY, Fernandez-Otiz A, Macaya C, Pintor E, Lindpaintner K, Fernandez-Cruz A. Lipid metabolism and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: role of cholesteryl ester transfer protein and paraoxonase/arylesterase. J Thromb Haemost. 2003;1:1202-1207.
41. Park KW, Choi JH, Kim HK, Oh S, Chae IH, Kim HS, et al. The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Koreans. Clin Genet. 2003;63:31-38.
42. Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J. 2003;24:1833-1842.
43. Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis. 2002;161:469-474.
44. Wu JH, Lee YT, Hsu HC, Hsieh LL. Influence of CETP gene variation on plasma lipid levels and coronary heart disease: a survey in Taiwan. Atherosclerosis. 2001;159:451-458.
45. Arca M, Montali A, Ombres D, Battiloro E, Campagna F, Ricci G, et al. Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet. 2001;60:374-380.
46. Tenkanen H, Koshinen P, Kontula K, Aalto-Setälä K, Mänttäri M, Manninen V, et al. Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease. Hum Genet. 1991;87:574-578.
47. Mendis S, Shepherd J, Packard CJ, Gaffney D. Genetic variation in the cholesteryl ester transfer protein and apolipoprotein A-I genes and its relation to coronary heart disease in a Sri Lankan population. Atherosclerosis. 1990;83:21-27.
48. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2:26-33. doi: 10.1161/CIRCGENETICS.108.817304.
49. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(Pt 2):111-124. doi: doi:10.1017/S0003480002001057.
50. Brousseau ME, O'Connor JJ Jr, Ordovas JM, Collins D, Otvos JD, Massov T, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol. 2002;22:1148-1154.
51. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol. 2000;20:1323-1329.
52. Corella D, Sáiz C, Guillén M, Portolés O, Mulet F, González JI, et al. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis. 2000;152:367-376.
53. Gudnason V, Kakko S, Nicaud V, Savolainen MJ, Kesäniemi YA, Tahvanainen E, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest. 1999;29:116-128.
54. Kauma H, Savolainen MJ, Heikkilä R, Rantala AO, Lilja M, Reunanen A, et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Hum Genet. 1996;97:156-162.
55. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature . 1993;364:73-75. doi: 10.1038/364073a0.
56. Wu Z, Lou Y, Qiu X, Liu Y, Lu L, Chen Q, et al. Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach. BMC Med Genet. 2014;15:118. doi: 10.1186/s12881-014-0118-1.
57. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50:S201-S206. doi: 10.1194/jlr.R800061-JLR200.
58. Hooper AJ, Burnett JR. Anacetrapib, a cholesteryl ester transfer protein inhibitor. Expert Opin Investig Drugs. 2012;21:103-109. doi: 10.1517/13543784.2012.642499.
59. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease [Epub ahead of print]. Eur Heart J. 2014.
60. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960-968. doi: 10.1093/eurheartj/ehu107.
61. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346. doi: 10.1038/nm.2937.
62. Durrington PN. Cholesteryl ester transfer protein (cetp) inhibitors. Br J Cardiol. 2012;19:126-133.
63. Rashedi N, Brennan D, Kastelein JJ, Nissen SE, Nicholls N. Impact of cholesteryl ester transfer protein inhibition on nuclear magnetic resonance derived lipoprotein particle parameters. Atheroscle Suppl. 2011;12:48-48.
64. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.